Nexalin Technology (NXL) Income from Continuing Operations (2021 - 2026)
Nexalin Technology's (NXL) quarterly Income from Continuing Operations came in at 2096837.0 in Q1 2026, down 5.51% year-on-year from 2219167.13 in Q1 2025, and up 11.77% quarter-over-quarter from 2376546.0 in Q4 2025.
Nexalin Technology (NXL) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Nexalin Technology's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 2096837.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 5.51% year-over-year to 2096837.0 in Q1 2026; TTM through Mar 2026 was 8330681.0, a 2.54% increase from a year earlier, with the FY2025 full-year figure at 6495133.0, up 14.62% from the prior year.
- Income from Continuing Operations improved to 2096837.0 in Q1 2026 per NXL's latest filing, from 2376546.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 303646.0 in Q3 2022 and bottomed at 2828624.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 1283202.0 (2024), against an average of 1440285.76.
- Across the five-year window, Income from Continuing Operations soared 83.34% in 2022 and slumped 656.54% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 763999.0 in 2022, then retreated by 2.18% to 780669.0 in 2023, then slumped by 262.33% to 2828624.0 in 2024, then advanced by 15.98% to 2376546.0 in 2025, then climbed by 11.77% to 2096837.0 in 2026.
- Per Business Quant, the three latest NXL Income from Continuing Operations figures stand at 2096837.0 (Q1 2026), 2376546.0 (Q4 2025), and 2276311.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.39 Bn | 174.10 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.38 Bn | 125.50 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.68 Bn | 98.46 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.98 Bn | 66.53 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 47.81 Bn | 44.13 Bn | 1.29 Bn | 380.70 Mn |
| 6 | GE HealthCare Technologies | 28.53 Bn | 26.25 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Dexcom | 28.35 Bn | 27.24 Bn | 750.30 Mn | 199.50 Mn |
| 8 | Smith & Nephew | 26.78 Bn | 26.20 Bn | - | - |
| 9 | Koninklijke Philips | 25.34 Bn | 22.21 Bn | 2.07 Bn | 273.95 Mn |
| 10 | Nexalin Technology | 9.52 Mn | 6.81 Mn | 13,133.00 | -2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.10 Mn |
| Dec 31, 2025 | -2.38 Mn |
| Sep 30, 2025 | -2.28 Mn |
| Jun 30, 2025 | -1.58 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | -2.83 Mn |
| Sep 30, 2024 | -2.45 Mn |
| Jun 30, 2024 | -1.28 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -780,669.00 |
| Sep 30, 2023 | -2.30 Mn |
| Jun 30, 2023 | -822,437.00 |
| Mar 31, 2023 | -748,414.00 |
| Dec 31, 2022 | -763,999.00 |
| Sep 30, 2022 | -303,646.00 |
| Jun 30, 2022 | -450,103.00 |
| Mar 31, 2022 | -393,249.00 |
| Dec 31, 2021 | -516,609.00 |
| Sep 30, 2021 | -1.82 Mn |